Tarsus Pharmaceuticals Azioni (NASDAQ: TARS)

Ultime notizie per Tarsus Pharmaceuticals (NASDAQ:TARS) Azioni

Tarsus Pharmaceuticals

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.

Tarsus Pharmaceuticals, Inc. - Common Stock

Tarsus Pharmaceuticals Inc

Silver North Resources Ltd

SILVER NORTH RESOURCES by SILVER NORTH RESOURCES LTD.

Tarsier Ltd

Tarsin Mobile Inc

Wolfe Research analyst Andy Chen upgrades Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) from Peer Perform to Outperform and announces $21 price target.

News

Upgrades

Price Target

Analyst Ratings

NTLA

Wolfe Research Upgrades Intellia Therapeutics to Outperform, Announces $21 Price Target

Northland Capital Markets analyst Mike Grondahl initiates coverage on Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) with a Outperform rating and announces Price Target of $20.

Initiation

Northland Capital Markets Initiates Coverage On Hut 8 with Outperform Rating, Announces Price Target of $20

Wolfe Research analyst Devin Brisco upgrades Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) from Peer Perform to Outperform and announces $660 price target.

SPOT

Wolfe Research Upgrades Spotify Technology to Outperform, Announces $660 Price Target

Klaus Schwab, Founder and Chairman of the World Economic Forum&#8217;s (WEF) Board of Trustees, has officially resigned after 55 years of service in the Geneva-based institution.
Schwab, who is entering his 88th year, informed the Board of Trustees of his decision, effective immediately.
&#8220;Following my recent announcement, and as I enter my 88th year, I have decided to step down from the position of Chair and as a member of the Board of Trustees, with immediate effect,&#8221; Schwab stated in an official release from the Forum.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44724763/pharma-industry-faces-jitters-as-trump-hints-at-historic-tariffs-bofa-outlines-probable-timeline" rel="noreferrer noopener">Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline</a>
At an extraordinary meeting on 20 April, the Board of Trustees <a target="_blank" href="https://www.weforum.org/press/2025/04/world-economic-forum-announces-governance-transition/" rel="noreferrer noopener">noted</a> Klaus Schwab&#8217;s resignation. In accordance with the Forum&#8217;s Rules and Regulations, the Board unanimously appointed Vice Chairman Peter Brabeck-Letmathe as Chairman ad interim. It also established a Search Committee to select a future Chair.
&#8220;At a time when the world is undergoing rapid transformation, the need for inclusive dialogue to navigate complexity and shape the future has never been more critical. The Board of Trustees of the World Economic Forum underlines the importance of remaining steadfast in its mission and values as a facilitator of progress,&#8221; the institution said in a press release on Monday.
In January, the World Economic Forum <a target="_blank" href="https://www.novartis.com/events/world-economic-forum-annual-meeting-2025" rel="noreferrer noopener">held</a> its Annual Meeting in Davos-Klosters. The event brought together over 350 government leaders, including 60 heads of state and government.
U.S. President Donald Trump made a&nbsp;special address&nbsp;at Davos just three days after being inaugurated as the 47th president.
Trump <a target="_blank" href="https://www.weforum.org/stories/2025/01/davos-2025-special-address-donald-trump-president-united-states/" rel="noreferrer noopener">said</a> his administration is working to fix the &#8216;economic chaos&#8217; and will make the U.S. &#8216;stronger, wealthier and more united than ever before&#8217;.
He added that he would work to bring down oil and gas prices, eliminate regulations, introduce tax cuts for domestic producers, and impose tariffs on foreign goods.
The Wall Street Journal <a target="_blank" href="https://www.wsj.com/business/davos-founder-klaus-schwab-to-step-aside-as-forums-chair-0f3231b0" rel="noreferrer noopener">reports</a> that the World Economic Forum has been making leadership changes recently after the Board reviewed the results of a workplace culture investigation.
The probe followed a Journal article last year in which employees accused the organization of discriminating against women and Black people.
The Forum denied the report, and founder Klaus Schwab rejected the claims against him.
In a recent memo, CEO Børge Brende said the investigation didn&#8217;t confirm the allegations against Schwab but did highlight leadership issues that the Forum plans to address.
A spokesperson told WSJ that the Forum is now looking for a new chair and plans to complete the process by January 2027.
Several top executives are leaving, including Chief Legal Officer Nicola Port, tech and digital services head Malte Godbersen, and Managing Director Olivier Schwab, the founder&#8217;s son. His daughter Nicole Schwab also left the Forum in December.
The WSJ report added, citing a staff memo, that two senior managing directors—Saadia Zahidi and Jeremy Jurgens—had some of their duties reduced as part of a recent reorganization.
&#8220;Over these past months, we have taken time—time to pause, to listen, and to reflect,&#8221; Brende said in the memo. &#8220;This period of reflection has been grounded in a desire not just to do things differently, but to do them better.&#8221;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44897214/nvidia-discusses-ai-powering-future-with-japan-amid-rising-energy-demands" target="_blank" rel="noreferrer noopener">Nvidia&#8217;s Jensen Huang Meets Japanese PM To Discuss AI&#8217;s Growing Energy Needs</a></li>
</ul>
Photo by Boris-B via Shutterstock

Government

General

World Economic Forum Chair Klaus Schwab Resigns After 55 Years, Interim Successor Takes Over

Wolfe Research analyst Peter Supino upgrades Walt Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) from Peer Perform to Outperform and announces $112 price target.

Wolfe Research Upgrades Walt Disney to Outperform, Announces $112 Price Target

Scotiabank analyst Brandon Bingham maintains Kinder Morgan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>) with a Sector Perform and raises the price target from $25 to $26.

Scotiabank Maintains Sector Perform on Kinder Morgan, Raises Price Target to $26

Analysts highlight advertising revenue growth and future catalysts for Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) after the company beat first-quarter revenue and <a href="https://www.benzinga.com/general/entertainment/25/04/44877995/netflix-crushes-q1-says-its-working-hard-to-improve-and-expand-its-offering">earnings per share estimates</a>.
<h2 class="wp-block-heading">The Netflix Analysts</h2>
<ul>
<li>Macquarie analyst Ross Compton maintained an Outperform rating on Netflix and raised the price target from $1,150 to $1,200.</li>
<li>JPMorgan analyst Doug Anmuth reiterated an Overweight rating and raised the price target from $1,025 to $1,150.</li>
<li>KeyBanc analyst Justin Patterson maintained an Overweight rating and raised the price target from $1,000 to $1,070.</li>
<li>Benchmark analyst Matthew Harrigan maintained a Hold rating with no price target.</li>
<li>Needham analyst Laura Martain maintained a Buy rating with a $1,126 price target.</li>
<li>Wedbush analyst Alician Reese reiterated an Outperform rating and raised the price target from $1,150 to $1,200.</li>
</ul>
Macquarie: Advertising monetization could give Netflix a competitive advantage, Compton said in a new investor note.
"Mgmt confirmed they are not seeing a slowdown or pullback in add spend given recent macro uncertainty," he said.
Future catalysts for Netflix include further price increases and the company's upcoming content slate, Compton added. "Its ad-tier represents a broadened and deepened that comfortably paves multi-year double-digit top line growth."
Read Also: <a href="https://www.benzinga.com/general/entertainment/25/03/44574912/elon-musk-attacks-netflix-hit-series-shares-anti-white-propaganda-allegation-heres-how-the-shows-writer-claps-back">Elon Musk Attacks Netflix Hit Series, Shares &#8216;Anti-White Propaganda&#8217; Allegation: Here&#8217;s How The Show&#8217;s Writer Claps Back</a>
JPMorgan: The streaming company is "playing offense," while its stock remains defensive, Anmuth said in a new investor note.
The analyst said Netflix's first-quarter financial results and outlook were "solid" and point to confidence in the 2025 full-year results.
Anmuth said that double-digit revenue growth supports Netflix&#8217;s bull thesis. He also cited operating margin expansion, improving profit and cash content discipline, a strong leadership position, and the company's potential to become a global TV company with international expansion.
"We believe NFLX is a key beneficiary and driver of the ongoing disruption of linear TV, with Netflix's content performing well globally and driving a virtuous circle of strong subscriber growth, more revenue, and growing profit," Anmuth said.
KeyBanc: The streaming giant highlighted its minimal impact from tariffs and macroeconomic concerns along with strength for its advertising business, Patterson said in a new investor note.
"Netflix's 1Q results reinforced that the Company is relatively insulated from the macro, has 2H catalysts (Stranger Things, Wednesday), and a margin cushion," Patterson said.
The analyst said ad personalization is still in the early innings and Netflix should benefit from its ad-tech platform going forward.
"We believe Netflix is poised for more balanced growth between subscribers and monetization over the MT."
Benchmark: Harrigan said in a new investor note that Netflix shares could be fairly valued despite the bulls&#8217; proposition that they are a safe-haven stock.
The analyst said the stock may provide a buffer against Trump tariffs and global recession, but has limited upside to the stock price.
"Given management's decision not to continue reporting quarterly member tallies we have now pivoted our primary valuation sensitivity to realized 2030 revenue and operating margins," Harrigan said.
Harrigan said Netflix would be "considerably overvalued" if traded as a media company.
Needham: The streaming giant faced more questions about advertising given it no longer breaks out subscriber figures or paid member growth, Martin said in a new analyst note.
"NFLX stated that it has seen no meaningful changes in retention, churn, or plan mix owing to tariffs or a slowing economy," Martin said.
The analyst said Netflix sees its ad-tier ($7.99/month) as a defensive move to keep churn low. The company said it expects advertising revenue to double in 2025.
Martin said the things to like the most about Netflix are global scale, price increases, bundling with other services and advertising revenue growth accelerating. Wedbush: With a "virtually insurmountable lead in the streaming wars," Netflix gets a price target increase from Reese in a new investor note.
The analyst said Netflix's first-quarter results likely came with higher subscriber additions and revenue per member, despite the company no longer sharing these figures.
"Even with higher pricing, offering its members a vast library of original and licensed content and the option to trade down to less expensive tiers has significantly limited churn," Reese said.
Reese said Netflix is also positioned to boost its ad-tier with live events and improved advertising solutions.
"While massive subscribers growth was the primary driver in 2024, we expect price increases to drive revenue growth in 2025, and the ad tier to drive revenue higher in 2026."
Price Action: Netflix stock is up 2.6% to $998.74 on Monday versus a 52-week trading range of $542.01 to $1,064.50. Netflix stock is up 12.6% year-to-date in 2025.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/sports/25/03/44291855/netflix-stock-to-kick-and-punch-higher-streamer-could-add-ufc-rights-to-its-growing-sports-library">Netflix Stock To Kick And Punch Higher? Streamer Could Add UFC Rights To Its Growing Sports Library</a></li>
</ul>
Image: Shutterstock

Analyst Color

Entertainment

Reiteration

Trading Ideas

NFLX

Netflix 'Playing Offense' While Stock Plays Defense: 6 Analysts On Q1 Results, Advertising Growth Ahead

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) briefly tapped $88,000 in Monday trading, eliciting bullish calls from traders that cite a strong high-timeframe structure and <a href="https://www.benzinga.com/money/bitcoin-price-prediction">improving macro backdrop</a>.
What Happened: Crypto trader Astronomer <a href="https://x.com/astronomer_zero/status/1914332318841622646">flagged</a> the move as significant, calling $88,000 a key target from his original bottom thesis. 
Despite hitting this milestone, he has not opened short positions, citing a lack of meaningful sell walls, ongoing order book strength and continued whale-led accumulation.
Astronomer says the only short trigger would be a sweep of $88,700, signs of whale distribution and local top signals. 
He expects any potential reversal to appear by Tuesday or Wednesday, ideally confirmed with a bearish weekly close. Until then, he's riding spot longs and is open to reloading at midrange levels.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44894280/how-traders-can-make-money-when-bitcoin-trades-sideways-10x-research">How Traders Can Make Money When Bitcoin Trades Sideways: 10x Research</a>
Why It Matters: Another trader, Nachi, <a href="https://x.com/alphawifhat/status/1914243855488360718?s=46">shared</a> that he entered BTC at $80,000 and Solana at $110, following President Trump's recent announcement of a 90-day pause on tariffs, a move he interprets as a sign that peak hawkishness may have passed.
Nachi maintains a bullish thesis, backed by the BTC/gold ratio holding strong, high-timeframe bullish structure, early signs of Bitcoin decoupling from equities, a weaker dollar amid fragile macro conditions and renewed central bank liquidity injection. 
What's Next: Nachi's base case is that Summer 2025 (April–August) could be the most bullish stretch, marking a pivot from maximum bearishness to easing macro trends. 
Rate cuts, stimulus measures, and softer trade policy could further fuel upside.
He notes one caveat: if Trump reverses his tariff stance by June, the bullish macro narrative could stall, but until then, the trend looks up.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44896411/bitcoin-catapults-to-87000-what-is-going-on">Bitcoin Catapults To $87,000: What Is Going On?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Briefly Hits $88,000: What's Next?

Scotiabank analyst Nat Schindler maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Sector Perform and lowers the price target from $627 to $525.

Scotiabank Maintains Sector Perform on Meta Platforms, Lowers Price Target to $525

Evercore ISI Group analyst Samir Khanal maintains Rexford Industrial Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REXR#NYSE">REXR</a>) with a Outperform and lowers the price target from $43 to $40.

REXR

Evercore ISI Group Maintains Outperform on Rexford Industrial Realty, Lowers Price Target to $40

<a href="https://www.biopharmadive.com/news/novo-oral-semaglutide-fda-approval-application-obesity/745882/">https://www.biopharmadive.com/news/novo-oral-semaglutide-fda-approval-application-obesity/745882/</a>

Biotech

Novo Announces It Has Submitted Its Obesity Pill For FDA Approval

Evercore ISI Group analyst Mark Mahaney maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Outperform and raises the price target from $1100 to $1150.

Evercore ISI Group Maintains Outperform on Netflix, Raises Price Target to $1150

Scotiabank analyst Nat Schindler maintains Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) with a Sector Outperform and lowers the price target from $232 to $200.

GOOG

GOOGL

Scotiabank Maintains Sector Outperform on Alphabet, Lowers Price Target to $200

<a href="https://x.com/cgasparino/status/1914369956357267870?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg">https://x.com/cgasparino/status/1914369956357267870?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg</a>

TSLA

Charles Gasparino Posts On X "Breaking: Tesla investors expecting guidance during Tuesday's earnings call from @elonmusk on his future involvement in DOGE...."

Scotiabank analyst Nat Schindler maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Sector Outperform and lowers the price target from $306 to $250.

AMZN

Scotiabank Maintains Sector Outperform on Amazon.com, Lowers Price Target to $250

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates uniQure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) with a Buy and maintains $70 price target.

QURE

HC Wainwright & Co. Reiterates Buy on uniQure, Maintains $70 Price Target

<a href="https://x.com/presssec/status/1914371752685076757?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg">https://x.com/presssec/status/1914371752685076757?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg</a>

Politics

'White House Says NPR Report On Search For New Defense Secretary Is 'Fake News''

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROIV#NASDAQ">ROIV</a>) with a Buy and maintains $18 price target.

ROIV

HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $18 Price Target

Macquarie analyst Tim Nollen maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Outperform and raises the price target from $1150 to $1200.

Macquarie Maintains Outperform on Netflix, Raises Price Target to $1200

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RKLB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$10.00</td>
<td>$56.0K</td>
<td>341</td>
<td>2.0K</td>
</tr>
<tr>
<td>PBI</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$5.00</td>
<td>$271.5K</td>
<td>3.3K</td>
<td>1.7K</td>
</tr>
<tr>
<td>CAR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$75.00</td>
<td>$50.4K</td>
<td>98</td>
<td>980</td>
</tr>
<tr>
<td>ZIM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$16.66</td>
<td>$42.3K</td>
<td>12.7K</td>
<td>864</td>
</tr>
<tr>
<td>BA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/02/25</td>
<td>$155.00</td>
<td>$57.5K</td>
<td>489</td>
<td>432</td>
</tr>
<tr>
<td>LUV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$32.50</td>
<td>$28.6K</td>
<td>3.6K</td>
<td>32</td>
</tr>
<tr>
<td>CMI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$300.00</td>
<td>$39.3K</td>
<td>32</td>
<td>15</td>
</tr>
<tr>
<td>UAL</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/25/25</td>
<td>$91.00</td>
<td>$26.3K</td>
<td>10</td>
<td>14</td>
</tr>
<tr>
<td>GEV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$400.00</td>
<td>$101.5K</td>
<td>20</td>
<td>10</td>
</tr>
<tr>
<td>NOC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$535.00</td>
<td>$30.3K</td>
<td>38</td>
<td>5</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For RKLB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>), we notice a put option sweep that happens to be bearish, expiring in 60 day(s) on June 20, 2025. This event was a transfer of 2000 contract(s) at a $10.00 strike. This particular put needed to be split into 44 different trades to become filled. The total cost received by the writing party (or parties) was $56.0K, with a price of $28.0 per contract. There were 341 open contracts at this strike prior to today, and today 2005 contract(s) were bought and sold. 
• Regarding PBI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBI#NYSE">PBI</a>), we observe a call option trade with neutral sentiment. It expires in 634 day(s) on January 15, 2027. Parties traded 724 contract(s) at a $5.00 strike. The total cost received by the writing party (or parties) was $271.5K, with a price of $375.0 per contract. There were 3331 open contracts at this strike prior to today, and today 1726 contract(s) were bought and sold. 
• Regarding CAR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>), we observe a put option sweep with bearish sentiment. It expires in 116 day(s) on August 15, 2025. Parties traded 46 contract(s) at a $75.00 strike. This particular put needed to be split into 38 different trades to become filled. The total cost received by the writing party (or parties) was $50.4K, with a price of $1097.0 per contract. There were 98 open contracts at this strike prior to today, and today 980 contract(s) were bought and sold. 
• Regarding ZIM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>), we observe a call option sweep with bullish sentiment. It expires in 270 day(s) on January 16, 2026. Parties traded 368 contract(s) at a $16.66 strike. This particular call needed to be split into 18 different trades to become filled. The total cost received by the writing party (or parties) was $42.3K, with a price of $115.0 per contract. There were 12704 open contracts at this strike prior to today, and today 864 contract(s) were bought and sold. 
• Regarding BA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>), we observe a put option trade with bullish sentiment. It expires in 11 day(s) on May 2, 2025. Parties traded 101 contract(s) at a $155.00 strike. The total cost received by the writing party (or parties) was $57.5K, with a price of $570.0 per contract. There were 489 open contracts at this strike prior to today, and today 432 contract(s) were bought and sold. 
• Regarding LUV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>), we observe a put option sweep with bearish sentiment. It expires in 151 day(s) on September 19, 2025. Parties traded 32 contract(s) at a $32.50 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $28.6K, with a price of $895.0 per contract. There were 3694 open contracts at this strike prior to today, and today 32 contract(s) were bought and sold. 
• Regarding CMI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>), we observe a call option trade with bearish sentiment. It expires in 423 day(s) on June 18, 2026. Parties traded 15 contract(s) at a $300.00 strike. The total cost received by the writing party (or parties) was $39.3K, with a price of $2620.0 per contract. There were 32 open contracts at this strike prior to today, and today 15 contract(s) were bought and sold. 
• For UAL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>), we notice a put option trade that happens to be neutral, expiring in 4 day(s) on April 25, 2025. This event was a transfer of 10 contract(s) at a $91.00 strike. The total cost received by the writing party (or parties) was $26.3K, with a price of $2633.0 per contract. There were 10 open contracts at this strike prior to today, and today 14 contract(s) were bought and sold. 
• Regarding GEV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>), we observe a put option trade with bearish sentiment. It expires in 116 day(s) on August 15, 2025. Parties traded 10 contract(s) at a $400.00 strike. The total cost received by the writing party (or parties) was $101.5K, with a price of $10150.0 per contract. There were 20 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
• Regarding NOC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>), we observe a put option trade with bearish sentiment. It expires in 25 day(s) on May 16, 2025. Parties traded 15 contract(s) at a $535.00 strike. The total cost received by the writing party (or parties) was $30.3K, with a price of $2020.0 per contract. There were 38 open contracts at this strike prior to today, and today 5 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

RKLB

10 Industrials Stocks Whale Activity In Today's Session

Management

Press Releases

Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors

Earnings

Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements

Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care

Tarsus to Participate in Upcoming Investor Conferences

Penny Stocks

Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual Meeting

Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025

Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements

Tarsus to Participate in Upcoming Investor Conference

Markets

Tarsus Announces Proposed $100.0 Million Public Offering

Health Care

Tarsus Announces Pricing of Upsized $125.0 Million Public Offering

AVTE

CTRX

DVAX

HPTX

HZNP

MRNA

TARS

ZNTL

ZSPH

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharma

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

ANI Pharmaceuticals

Axsome Therapeutics

Belite Bio, Inc - American Depositary Shares

Belite Bio

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Harmony Biosciences Holdings, Inc. - Common Stock

Harmony Biosciences Hldgs

Indivior

Innoviva

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Liquidia

Ocular Therapeutix

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pacira BioSciences

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Supernus Pharmaceuticals, Inc. - Common Stock

Supernus Pharmaceuticals

Verona Pharma plc - American Depositary Shares

Comments

Tarsus Pharmaceuticals

Notizie

Ultime notizie per Tarsus Pharmaceuticals (NASDAQ:TARS) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO